Answers are grounded in this paper and cite their sources.
Highlights the ongoing clinical challenge of acute rejection in heart transplant recipients and the reliance on invasive endomyocardial biopsies for monitoring.
Among patients undergoing heart transplantation, a fundamental clinical concern is the risk of rejection of the new organ. Although modern immunosuppressive regimens have reduced the incidence of rejection substantially, about one quarter of recipients will still have a rejection episode requiring treatment during the first year after transplantation.1 Acute rejection is the cause of 12% of deaths occurring between 1 month and 1 year after transplantation.1 There is no established noninvasive marker of rejection available for heart-transplant recipients; instead they must undergo serial endomyocardial biopsies with histologic evaluation of myocardial tissue to monitor for rejection. Endomyocardial biopsy is an invasive . . .
No takes yet. Share an insight, caveat, or question.
John A. Jarcho (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: